Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, Graves Ophthalmopathy, Graves disease, Hashimoto thyroiditis, autoimmune disease, autoimmune thyroid disease, disease of orbital part of eye adnexa, endocrine system disorder, exophthalmos, eye disorder, goiter, hereditary disease, hyperthyroidism, immune system disorder, thyroid gland disorder, thyroiditis	Recruiting	Phase 2 / Phase 3	2025-02-25		NCT06112340

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Sling Therapeutics, Inc.	2

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Bascom Palmer Eye Institute	Miami	United States	17
West Virginia University Eye Institute	Morgantown	United States	4